ALLO β€” ALLOGENE THERAPEUTICS INC

Ownership history in DAFNA Capital Management LLC  Β·  7 quarters on record

This page tracks every 13F SEC filing in which DAFNA Capital Management LLC reported a position in ALLOGENE THERAPEUTICS INC (ALLO). Data includes quarterly share count, position size as % of portfolio, estimated market value, and end-of-quarter stock price β€” sourced directly from SEC EDGAR 13F filings.

πŸ” Peak position
0.69% (2024 Q3)
πŸ“Š Avg. % of fund
0.51%
πŸ“… First filed
2024 Q2
πŸ“… Last filed
2025 Q4
⏱ Quarters held
7

Position Intelligence

DAFNA Capital Management LLC Γ— ALLO AI Analytics

πŸ“‰ DAFNA Capital Management LLC underperformed the S&P 500 by –62.0% annually on this ALLO position. Timing score: 0% (0/3 decisions correct). Average cost basis: $2.39. Maximum drawdown during holding period: –59.6%.

πŸ“ˆ Position Alpha vs SPY
-62.0%
annualised excess return

❌ Significantly underperformed the S&P 500 by 62.0% ann.
5 quarters analyzed

⏱️ Timing Score
0%

⚠️ Poor timing β€” buys often preceded drops, trims preceded rallies.
0 of 3 add/trim decisions correct

πŸ’° Entry Quality
$2.39
-42.7% vs current ($1.37)

Best entry: $1.46 (2025 Q1)  Β·  Worst: $2.80 (2024 Q3)

πŸ›‘οΈ Drawdown Resilience
–59.6%
max drawdown while held

πŸ’ͺ Held through 1 major drawdown (>20%). Strong conviction under pressure.

πŸ’ͺ Fund Conviction
100%
buy-side decisions

4 adds Β· 0 trims. Bought during 2 of 3 down-price quarters. πŸ‚ Consistently bullish β€” fund kept accumulating this position.

πŸ“‘ Position Trajectory
↓ Shrinking
last 4–5 quarters trend

πŸ“‰ Portfolio weight has been declining in recent quarters. Possible distribution phase.
Currently 0.44% of portfolio

⚠ Based on quarterly 13F SEC filings and end-of-quarter closing prices. Timing score = accuracy of add/trim decisions vs next-quarter price direction. Alpha = mean quarterly excess return Γ— 4 (annualised). Not investment advice.

% of Fund (quarterly)    ALLO price (monthly, adj. close)
πŸ“‹ Quarterly Holdings History 7 quarters  β–Ύ
Quarter Action Shares Change Chg % % of Fund Mkt Value Price (EOQ)
2025 Q4 UNCHANGED 1,380,118 β€” 0% 0.44% $1.9M $1.37
2025 Q3 UNCHANGED 1,380,118 β€” 0% 0.42% $1.7M $1.24
2025 Q2 UNCHANGED 1,380,118 β€” 0% 0.43% $1.6M $1.13
2025 Q1 ADDED 1,380,118 +140,000 +11.3% 0.57% $2.0M $1.46
2024 Q4 ADDED 1,240,118 +190,000 +18.1% 0.67% $2.6M $2.13
2024 Q3 ADDED 1,050,118 +445,018 +73.5% 0.69% $2.9M $2.80
2024 Q2 INITIATED 605,100 β€” β€” 0.34% $1.4M β€”

🏒 Other funds also holding ALLO

As of 2025 Q4 β€” sorted by position size

PFIZER INC 12.76% Wildcat Capital Management, LLC 3Y 7Y 2.93% Patient Square Capital LP 3Y 1.46% TPG GP A, LLC 3Y 0.95% Frazier Life Sciences Management, L.P. 3Y 0.14% GSA CAPITAL PARTNERS LLP 3Y 7Y 0.07% Virtus Investment Advisers, LLC 3Y 7Y 0.07% Woodline Partners LP 3Y 0.02% XTX Topco Ltd 3Y 0.02% Navalign, LLC 3Y 0.02%
← Back to DAFNA Capital Management LLC Holdings